The primary tablet model of the blockbuster GLP-1 weight reduction medicine has been launched within the US by Novo Nordisk at a decrease value than jab varieties, accelerating a worth conflict within the sector.
Support Greater and Subscribe to view content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
